Dark

Check out our Level2View

ANGN
Angion Biomedica Corp. Common Stock
stock NASDAQ

Inactive

Jun 1, 2023

10.00USD+2.041%(+0.20)22,485

Pre-market

0.00USD-100.000%(-9.80)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 5, 2022

08:20AM EST The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets Benzinga

Jan 4, 2022

04:09PM EST Angion Biomedica Reports First Patient Dosed In Phase 2 Trial Of ANG-3070 In Patients with Primary Proteinuric Kidney Diseases; Sees Ending 2021 With ~$88.8M In Cash, Cash Equivalents Benzinga

04:05PM EST -- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases GlobeNewswire Inc

Dec 10, 2021

02:34PM EST Mid-Day Market Update: Oracle Gains Following Upbeat Q2 Results; Angion Biomedica Shares Drop Benzinga

02:33PM EST Mid-Afternoon Market Update: Dow Rises 150 Points; SigmaTron International Shares Spike Higher Benzinga

12:40PM EST Mid-Day Market Update: Oracle Gains Following Upbeat Q2 Results; Angion Biomedica Shares Drop Benzinga

09:53AM EST Mid-Morning Market Update: Markets Open Higher; Inflation Rate Increases To 6.8% Benzinga

07:50AM EST The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares Benzinga

07:19AM EST Oppenheimer Maintains Outperform on Angion Biomedica, Lowers Price Target to $8 Benzinga

01:35AM EST A phase-II GUARD trial of Angion's ANG-3777 in cardiac surgery associated acute kidney injury did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve or AUC, Vifor Pharma and Angion Biomedica Corp. (ANGN) said in a statement. RTTNews

01:05AM EST Vifor : Phase-II GUARD Trial Of ANG-3777 In Cardiac Surgery Associated Acute Kidney Injury Didn't Meet Primary Goal RTTNews

01:00AM EST Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury Business Wire

Dec 9, 2021

09:57PM EST Angion and Vifor Pharma Report Topline Results From Phase 2 GUARD Trial Of ANG-3777 In Cardiac Surgery-Associated Acute Kidney Injury Benzinga

04:05PM EST Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD GlobeNewswire Inc

Nov 12, 2021

07:15AM EST Angion Biomedica Q3 EPS $(0.53) Up From $(1.19) YoY, Sales $1.50M Benzinga

07:00AM EST Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the quarter ended September 30, 2021. GlobeNewswire Inc

Nov 9, 2021

11:37AM EST HC Wainwright & Co. Maintains Buy on Angion Biomedica, Lowers Price Target to $50 Benzinga

Nov 2, 2021

01:30AM EDT Angion to Participate in Upcoming Investment Conference GlobeNewswire Inc

Oct 27, 2021

02:40PM EDT Mid-Afternoon Market Update: Nasdaq Surges Over 100 Points; Cortexyme Shares Plunge Benzinga

12:15PM EDT Mid-Day Market Update: Dow Falls Over 100 Points; Silicon Laboratories Shares Spike Higher Benzinga

08:27AM EDT Stifel Maintains Buy on Angion Biomedica, Lowers Price Target to $15 Benzinga

06:13AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 05.55 A.M. EDT). RTTNews

Oct 26, 2021

04:49PM EDT Angion And Vifor Pharma Report Topline Results From Phase 3 Trial Of ANG-3777; Study Did Not Demonstrate A Statistically Significant Difference From Placebo On The Primary Endpoint Benzinga

04:05PM EDT Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angions ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF). GlobeNewswire Inc

Oct 18, 2021

04:05PM EDT Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced it will be presenting four posters at the American Society of Nephrologys Kidney Week 2021 virtual meeting to be held November 4-7, 2021. GlobeNewswire Inc

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Sep 8, 2021

12:05AM EDT Angion Hosting Research & Development Day on ANG-3070 for the GlobeNewswire Inc

Sep 2, 2021

12:20AM EDT Angion to Participate in Upcoming September Investment Conferences GlobeNewswire Inc

Aug 30, 2021

07:11AM EDT Angion Biomedica Says On Aug. 27 Received Written Notice From Sinovant Stating Sinovant Intents To Terminate Exclusive License Agreement With Co. Dated Aug. 22 Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 12, 2021

04:57PM EDT Angion Biomedica Q2 EPS $(0.58) Up From $(1.40) YoY Benzinga

04:05PM EDT -- Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end GlobeNewswire Inc

Aug 3, 2021

08:36AM EDT Angion Earlier Today Reported Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021 Benzinga

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

12:05AM EDT Angion Reports Positive Results from Phase 1 Healthy Volunteer GlobeNewswire Inc

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jul 2, 2021

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jun 30, 2021

08:17AM EDT Angion Stock Falls As Lead Product Candidate Flunks In COVID-19 Trial Benzinga

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 29, 2021

05:37PM EDT Angion Biomedica Corp. (ANGN) Tuesday evening said that its mid-stage trial of lead candidate ANG-3777 in patients with Covid-19 vaccine related pneumonia at high risk for acute respiratory distress syndrome (ARDS) did not meet the primary or secondary efficacy endpoints. RTTNews

05:15PM EDT Angion Announces Results From Phase 2 ALI-201 Study In Patients With COVID-19 Associated Pneumonia RTTNews

04:06PM EDT Angion Announces Phase 2 ALI-201 Study Did Not Meet Primary Or Secondary Efficacy Endpoint Benzinga

04:05PM EDT Angion Announces Results from the Phase 2 ALI-201 Study in GlobeNewswire Inc

Jun 9, 2021

09:14AM EDT The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US Benzinga

May 17, 2021

07:24AM EDT Angion Biomedica Q1 EPS $(1.56) Down From $(0.91) YoY, Sales $371.00K Down From $865.00K YoY Benzinga

07:00AM EDT Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the quarter ended March 31, 2021. GlobeNewswire Inc

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Mar 30, 2021

04:15PM EDT Angion Biomedica Q4 EPS $(1.90) Down From $(1.11) YoY Benzinga

04:05PM EDT Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2020. GlobeNewswire Inc

Mar 25, 2021

12:05AM EDT Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute GlobeNewswire Inc

Mar 19, 2021

12:05AM EDT Angion Announces Partial Waiver of Certain Lock-up Restrictions GlobeNewswire Inc

Mar 2, 2021

01:11PM EST Cowen & Co. Initiates Coverage On Angion Biomedica with Outperform Rating Benzinga

11:05AM EST Oppenheimer Initiates Coverage On Angion Biomedica with Outperform Rating, Announces Price Target of $38 Benzinga

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021 Benzinga

09:43AM EST Stifel Initiates Coverage On Angion Biomedica with Buy Rating, Announces Price Target of $40 Benzinga

Mar 1, 2021

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021 Benzinga

06:43AM EST HC Wainwright & Co. Initiates Coverage On Angion Biomedica with Buy Rating, Announces Price Target of $100 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 24, 2021

12:05AM EST Angion to Participate in Upcoming March Investment Conferences GlobeNewswire Inc

Feb 19, 2021

07:25AM EST The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko Benzinga

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 17, 2021

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 9, 2021

04:10PM EST Angion Biomedica Corp. Announces Closing of $117 GlobeNewswire Inc

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 5, 2021

01:10PM EST Angion Biomedica Shares Open For Trade At $17.62; IPO Priced At $16/Share Benzinga

10:11AM EST Angion Biomedica Corp Shares Will Open For Quote At 11:25 a.m. EST, Expected To Open For Trade After 11:35 a.m. EST; IPO Priced At $16/Share Benzinga

08:34AM EST Angion Biomedica Corp. Prices 5M Share IPO At $16/Share Benzinga

08:30AM EST Angion Biomedica Corp. Announces Pricing of Initial Public GlobeNewswire Inc

Share